Studies with mouse tumor models of hepatocellular carcinoma (HCC) have shown that administration of WNT inhibitors (WIF-1, sFRP1) reduces the density of tumor vasculature, endothelial progenitor migration, and expression of pro-angiogenesis factors. The gene discussed is SFRP1; the disease is hepatocellular carcinoma.